{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T11:30:52Z","timestamp":1789212652026,"version":"build-2803163510"},"reference-count":42,"publisher":"Informa UK Limited","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Medical Research and Opinion"],"published-print":{"date-parts":[[2008,1]]},"DOI":"10.1185\/030079908x253816","type":"journal-article","created":{"date-parts":[[2009,4,14]],"date-time":"2009-04-14T10:41:07Z","timestamp":1239705667000},"page":"215-235","source":"Crossref","is-referenced-by-count":14,"title":["Decreasing the incidence and impact of infections in neutropenic patients: evidence from meta-analyses of randomized controlled trials"],"prefix":"10.1185","volume":"24","author":[{"given":"Matthew E.","family":"Falagas","sequence":"first","affiliation":[{"name":"Alfa Institute of Biomedical Sciences (AIBS)","place":["Greece"]},{"name":"Tufts University School of Medicine","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos Z.","family":"Vardakas","sequence":"additional","affiliation":[{"name":"Alfa Institute of Biomedical Sciences (AIBS)","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Samonis","sequence":"additional","affiliation":[{"name":"University of Crete School of Medicine","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2007,11,28]]},"reference":[{"key":"e_1_2_1_2_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-141-1-200407060-00014"},{"key":"e_1_2_1_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa072761"},{"key":"e_1_2_1_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(86)90046-2"},{"key":"e_1_2_1_5_1","first-page":"719","article-title":"Statistical aspects of the analysis of data from retrospective studies of disease","volume":"22","author":"Mantel N","year":"1959","unstructured":"Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959;22:719\u201348","journal-title":"J Natl Cancer Inst"},{"key":"e_1_2_1_6_1","unstructured":"Cochrane Collaboration. Review Manager 4.2 User guide. Acessed on October 30th 2007. http:\/\/www.cc-ims.net\/download\/revman\/Documentation\/User%20guide.pdf"},{"key":"e_1_2_1_7_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.315.7109.629"},{"key":"e_1_2_1_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.09.106"},{"key":"e_1_2_1_9_1","doi-asserted-by":"crossref","unstructured":"Sasse EC Sasse AD Brandalise S et al. Colony stimulating factors for prevention of myelosupressive therapy induced febrile neutropenia in children with acute lymphoblastic leukaemia. Cochrane Database Syst Rev 2005;CD004139","DOI":"10.1002\/14651858.CD004139.pub2"},{"key":"e_1_2_1_10_1","first-page":"406","volume":"112","author":"Lyman GH","year":"2002","unstructured":"Lyman GH, Kuderer NM, Djulbegovic B. Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy: a meta-analysis. Am J Med 2002;112:406\u201311","journal-title":"Djulbegovic B. Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy: a meta-analysis. Am J Med"},{"key":"e_1_2_1_11_1","first-page":"1302","article-title":"Knight A","volume":"90","author":"Hackshaw A","year":"2004","unstructured":"Hackshaw A, Sweetenham J, Knight A. Are prophylactic haematopoietic growth factors of value in the management of patients with aggressive non-Hodgkin\u2019s lymphoma? Br J Cancer 2004;90:1302\u20135","journal-title":"Are prophylactic haematopoietic growth factors of value in the management of patients with aggressive non-Hodgkin\u2019s lymphoma? Br J Cancer"},{"key":"e_1_2_1_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.06.1663"},{"key":"e_1_2_1_13_1","first-page":"979","volume":"142","author":"Gafter-Gvili A","year":"2005","unstructured":"Gafter-Gvili A, Fraser A, Paul M, et al. Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients. Ann Intern Med 2005;142:979\u201395","journal-title":"al. Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients. Ann Intern Med"},{"key":"e_1_2_1_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2005.03.006"},{"key":"e_1_2_1_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/23.4.795"},{"key":"e_1_2_1_16_1","first-page":"1179","volume":"16","author":"Engels EA","year":"1998","unstructured":"Engels EA, Lau J, Barza M. Efficacy of quinolone prophylaxis in neutropenic cancer patients: a meta-analysis. J Clin Oncol 1998;16:1179\u201387","journal-title":"Barza M. Efficacy of quinolone prophylaxis in neutropenic cancer patients: a meta-analysis. J Clin Oncol"},{"key":"e_1_2_1_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.01.234"},{"key":"e_1_2_1_18_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.314.7089.1238"},{"key":"e_1_2_1_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.10610"},{"key":"e_1_2_1_20_1","doi-asserted-by":"crossref","unstructured":"Kanda Y Yamamoto R Chizuka A et al. Prophylactic action of oral fluconazole against fungal infection in neutropenic patients. A meta-analysis of 16 randomized controlled trials. Cancer 2000;89: 1611\u201325","DOI":"10.1002\/1097-0142(20001001)89:7<1611::AID-CNCR27>3.0.CO;2-B"},{"key":"e_1_2_1_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.04.052"},{"key":"e_1_2_1_22_1","first-page":"22","volume":"131","author":"Vardakas KZ","year":"2005","unstructured":"Vardakas KZ, Michalopoulos A, Falagas ME. Fluconazole versus itraconazole for antifungal prophylaxis in neutropenic patients with haematological malignancies: a meta-analysis of randomised-controlled trials. Br J Haematol 2005; 131:22\u20138","journal-title":"Falagas ME. Fluconazole versus itraconazole for antifungal prophylaxis in neutropenic patients with haematological malignancies: a meta-analysis of randomised-controlled trials. Br J Haematol"},{"key":"e_1_2_1_23_1","first-page":"1408","volume":"193","author":"Eckmanns T","year":"2006","unstructured":"Eckmanns T, Ruden H, Gastmeier P. The influence of high efficiency particulate air filtration on mortality and fungal infection among highly immunosuppressed patients: a systematic review. J Infect Dis 2006;193:1408\u201318","journal-title":"Gastmeier P. The influence of high efficiency particulate air filtration on mortality and fungal infection among highly immunosuppressed patients: a systematic review. J Infect Dis"},{"key":"e_1_2_1_24_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.326.7399.1111"},{"key":"e_1_2_1_25_1","first-page":"231","volume":"2","author":"Furno P","year":"2002","unstructured":"Furno P, Bucaneve G, Del Favero A. Monotherapy or aminoglycoside-containing combinations for empirical antibiotic treatment of febrile neutropenic patients: a meta-analysis. Lancet Infect Dis 2002;2:231\u201342","journal-title":"Del Favero A. Monotherapy or aminoglycoside-containing combinations for empirical antibiotic treatment of febrile neutropenic patients: a meta-analysis. Lancet Infect Dis"},{"key":"e_1_2_1_26_1","first-page":"907","volume":"164","author":"Sanders JW","year":"1991","unstructured":"Sanders JW, Powe NR, Moore RD. Ceftazidime monotherapy for empiric treatment of febrile neutropenic patients: a meta-analysis. J Infect Dis 1991;164:907\u201316","journal-title":"Moore RD. Ceftazidime monotherapy for empiric treatment of febrile neutropenic patients: a meta-analysis. J Infect Dis"},{"key":"e_1_2_1_27_1","doi-asserted-by":"publisher","DOI":"10.1086\/514550"},{"key":"e_1_2_1_28_1","doi-asserted-by":"publisher","DOI":"10.4065\/80.9.1146"},{"key":"e_1_2_1_29_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dki448"},{"key":"e_1_2_1_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s005200000105"},{"key":"e_1_2_1_31_1","first-page":"29","volume":"54","author":"Vidal L","year":"2004","unstructured":"Vidal L, Paul M, Ben-Dor I, et al. Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients: a systematic review and meta-analysis of randomized trials. J Antimicrob Chemother 2004;54:29\u201337","journal-title":"Ben-Dor I, et al. Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients: a systematic review and meta-analysis of randomized trials. J Antimicrob Chemother"},{"key":"e_1_2_1_32_1","doi-asserted-by":"publisher","DOI":"10.1086\/339215"},{"key":"e_1_2_1_33_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dki028"},{"key":"e_1_2_1_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(05)70164-X"},{"key":"e_1_2_1_35_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/163.5.951"},{"key":"e_1_2_1_36_1","unstructured":"Johansen HK Gotzsche PC. Amphotericin B lipid soluble formulations vs. amphotericin B in cancer patients with neutropenia. Cochrane Database Syst Rev 2005;CD000969"},{"key":"e_1_2_1_37_1","unstructured":"Johansen HK Gotzsche PC. Amphotericin B versus fluconazole for controlling fungal infections in neutropenic cancer patients. Cochrane Database Syst Rev 2005;CD000239"},{"key":"e_1_2_1_38_1","doi-asserted-by":"crossref","unstructured":"Jorgensen KJ Gotzsche PC Johansen HK. Voriconazole versus amphotericin B in cancer patients with neutropenia. Cochrane Database Syst Rev 2006;CD00472","DOI":"10.1002\/14651858.CD004707.pub2"},{"key":"e_1_2_1_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0012-3692(15)33412-7"},{"key":"e_1_2_1_40_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dki355"},{"key":"e_1_2_1_41_1","doi-asserted-by":"crossref","unstructured":"Falagas ME Siempos II Vardakas KZ. Linezolid versus a glycopeptide or \u03b2-lactam for treatment of Gram-positive bacterial infections: a meta-analysis of randomized controlled trials. Lancet Infect Dis 2008 (in print)","DOI":"10.1016\/S1473-3099(07)70312-2"},{"key":"e_1_2_1_42_1","first-page":"2381","volume":"8","author":"Vardakas KZ","year":"2007","unstructured":"Vardakas KZ, Ntziora F, Falagas ME. Linezolid: effectiveness and safety for approved and off-label indications. Expert Opin Pharmacother 2007;8:2381\u2013400","journal-title":"Falagas ME. Linezolid: effectiveness and safety for approved and off-label indications. Expert Opin Pharmacother"},{"key":"e_1_2_1_43_1","first-page":"597","article-title":"Perez-Oteyza J, et al","volume":"42","author":"Jaksic B","year":"2006","unstructured":"Jaksic B, Martinelli G, Perez-Oteyza J, et al. Efficacy and safety of linezolid compared with vancomycin in a randomized, double-blind study of febrile neutropenic patients with cancer. Clin Infect Dis 2006;42:597\u2013607","journal-title":"Efficacy and safety of linezolid compared with vancomycin in a randomized, double-blind study of febrile neutropenic patients with cancer. Clin Infect Dis"}],"container-title":["Current Medical Research and Opinion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1185\/030079908X253816","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T23:10:36Z","timestamp":1770419436000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1185\/030079908X253816"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,11,28]]},"references-count":42,"aliases":["10.1185\/030079907x253816"],"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,1]]}},"alternative-id":["10.1185\/030079908X253816"],"URL":"https:\/\/doi.org\/10.1185\/030079908x253816","relation":{},"ISSN":["0300-7995","1473-4877"],"issn-type":[{"value":"0300-7995","type":"print"},{"value":"1473-4877","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,11,28]]}}}